Ninjurin1 in cardiovascular and vascular biology: From molecular mechanisms to therapeutic opportunities

Abstract

Background: Ninjurin1 (NINJ1) is a transmembrane protein originally identified as a nerve injury-induced adhesion molecule. Recent discoveries have revealed its essential role in plasma membrane rupture (PMR) during lytic cell death, positioning NINJ1 as a critical mediator at the intersection of vascular biology, inflammation, and programmed cell death. Its complex and context-dependent biology makes it a compelling target for cardiovascular research.

Methods: This review comprehensively synthesizes evidence from structural, molecular, cellular, and in vivo studies on NINJ1. We integrated data on NINJ1's structural biology, its cell-type-specific roles in endothelial cells, macrophages, smooth muscle cells, and pericytes, and its contributions to major cardiovascular diseases, including atherosclerosis, myocardial infarction, aortic aneurysm, and ischemia-reperfusion injury. Emerging therapeutic strategies targeting NINJ1 oligomerization were also evaluated.

Results: NINJ1 exhibits a fundamental biological paradox in cardiovascular pathophysiology. In its membrane-bound form, NINJ1 transitions from an autoinhibited homodimer to an active polymeric filament upon cell death stimulation, executing PMR and releasing damage-associated molecular patterns (DAMPs) that amplify vascular inflammation. In contrast, its soluble MMP-9-cleaved ectodomain (sNINJ1) suppresses macrophage activation, attenuates monocyte-endothelial interactions, and exerts potent atheroprotective effects. NINJ1 is dynamically regulated across multiple cardiovascular pathologies and contributes to endothelial dysfunction, plaque instability, myocardial injury, and pericyte-mediated vascular remodeling.

Conclusions: NINJ1 is a pivotal and therapeutically tractable mediator of cardiovascular inflammation. Its dual roles in promoting PMR-driven DAMP release and in limiting inflammation through sNINJ1 signaling provide complementary avenues for therapeutic intervention. Strategies targeting NINJ1 oligomerization or exploiting sNINJ1-mimetic peptides hold promise for the treatment of inflammatory cardiovascular diseases and warrant further translational investigation.

Key points:

Keywords

angiogenesis / atherosclerosis / cardiovascular disease / ischaemia‒reperfusion injury / Ninjurin1 / plasma membrane rupture

References

[1] Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019. J Am Coll Cardiol. 2020; 76(25): 2982-3021.

[2] Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017; 377(12): 1119-1131.

[3] Libby P, Buring JE, Badimon L, et al. Atherosclerosis. Nat Rev Dis Primer. 2019; 5(1): 56.

[4] Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019; 381(26): 2497-2505.

[5] Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002; 91(11): 988-998.

[6] Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial fibrillation. Nat Rev Cardiol. 2015; 12(4): 230-243.

[7] Araki T, Milbrandt J. Ninjurin, a novel adhesion molecule, is induced by nerve injury and promotes axonal growth. Neuron. 1996; 17(2): 353-361.

[8] Wang L, Zhao C, Xia Q-X, Qiao S-J. Association between 12p13 SNP rs11833579 and ischemic stroke in Asian population: an updated meta-analysis. J Neurol Sci. 2014; 345(1–2): 198-201.

[9] Jeon S, Kim TK, Jeong SJ, et al. Anti-inflammatory actions of soluble Ninjurin-1 ameliorate atherosclerosis. Circulation. 2020; 142(18): 1736-1751.

[10] Fang C, Jiao K, Zuo K, Yang X. Elevated plasma Ninjurin-1 levels in atrial fibrillation is associated with atrial remodeling and thromboembolic risk. BMC Cardiovasc Disord. 2022; 22(1): 153.

[11] Sahoo B, Mou Z, Liu W, Dubyak G, Dai X. How NINJ1 mediates plasma membrane rupture and why NINJ2 cannot. Cell. 2025; 188(2): 292-302. e11.

[12] David L, Borges JP, Hollingsworth LR, et al. NINJ1 mediates plasma membrane rupture by cutting and releasing membrane disks. Cell. 2024; 187(9): 2224-2235. e16.

[13] Kayagaki N, Kornfeld OS, Lee BL, et al. NINJ1 mediates plasma membrane rupture during lytic cell death. Nature. 2021; 591(7848): 131-136.

[14] Ramos S, Hartenian E, Santos JC, Walch P, Broz P, NINJ1 induces plasma membrane rupture and release of damage-associated molecular pattern molecules during ferroptosis. EMBO J. 2024; 43(7): 1164-1186.

[15] Whisstock JC, Law RHP. The role of NINJ1 protein in programmed cellular destruction. Nature. 2023; 618(7967): 912-914.

[16] Pourmal S, Truong ME, Johnson MC, et al. Autoinhibition of dimeric NINJ1 prevents plasma membrane rupture. Nature. 2025; 637(8045): 446-452.

[17] Degen M, Santos JC, Pluhackova K, et al. Structural basis of NINJ1-mediated plasma membrane rupture in cell death. Nature. 2023; 618(7967): 1065-1071.

[18] Lee HJ, Ahn BJ, Shin MW, Jeong JW, Kim JH, Kim KW. Ninjurin1 mediates macrophage-induced programmed cell death during early ocular development. Cell Death Differ. 2009; 16(10): 1395-1407.

[19] Kim SW, Lee HK, Seol SI, Davaanyam D, Lee H, Lee JK. Ninjurin 1 dodecamer peptide containing the N-terminal adhesion motif (N-NAM) exerts proangiogenic effects in HUVECs and in the postischemic brain. Sci Rep. 2020; 10(1):16656.

[20] Wang C, Dreyer B, Teran E, Ruan J. From pores to rupture: structural basis and regulation of lytic cell death by gasdermins and NINJ1. J Biol Chem. 2025; 301(10):110698.

[21] Deshpande I. cryoEM structure of NINJ1, a small cytotoxic membrane protein. Struct Dyn. 2025; 12(5_Supplement): A76.

[22] Lee C, Liang Y, Li Y. Structural and functional insights of NINJ1 in plasma membrane rupture during cell death. Mol Biomed. 2024; 5(1): 8.

[23] Kayagaki N, Stowe IB, Alegre K, et al. Inhibiting membrane rupture with NINJ1 antibodies limits tissue injury. Nature. 2023; 618(7967): 1072-1077.

[24] Xia S, Zhang Z, Magupalli VG, et al. Gasdermin D pore structure reveals preferential release of mature interleukin-1. Nature. 2021; 593(7860): 607-611.

[25] Ruan J, Xia S, Liu X, Lieberman J, Wu H. Cryo-EM structure of the gasdermin A3 membrane pore. Nature. 2018; 557(7703): 62-67.

[26] Dondelinger Y, Declercq W, Montessuit S, et al. MLKL compromises plasma membrane integrity by binding to phosphatidylinositol phosphates. Cell Rep. 2014; 7(4): 971-981.

[27] Zhu Y, Xiao F, Wang Y, et al. NINJ1 regulates plasma membrane fragility under mechanical strain. Nature. 2025; 644(8078): 1088-1096.

[28] Bae SJ, Shin MW, Kim RH, et al. Ninjurin1 assembles into a homomeric protein complex maintained by N-linked glycosylation. J Cell Biochem. 2017; 118(8): 2219-2230.

[29] Ahn BJ, Lee HJ, Shin MW, Choi JH, Jeong JW, Kim KW. Ninjurin1 is expressed in myeloid cells and mediates endothelium adhesion in the brains of EAE rats. Biochem Biophys Res Commun. 2009; 387(2): 321-325.

[30] Newby AC. Dual role of matrix metalloproteinases (Matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev. 2005; 85(1): 1-31.

[31] Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994; 94(6): 2493-2503.

[32] Loftus IM, Naylor AR, Goodall S, et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke. 2000; 31(1): 40-47.

[33] Ducharme A, Frantz S, Aikawa M, et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest. 2000; 106(1): 55-62.

[34] Lindsey ML. Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling. Nat Rev Cardiol. 2018; 15(8): 471-479.

[35] Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002; 37(6): 375-536.

[36] Thompson C. Protein proves to be a key link in innate immunity. Science. 1995; 269(5222): 301-302.

[37] Longo GM, Xiong W, Greiner TC, Zhao Y, Fiotti N, Baxter BT. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest. 2002; 110(5): 625-632.

[38] Devant P, Kagan JC. Molecular mechanisms of gasdermin D pore-forming activity. Nat Immunol. 2023; 24(7): 1064-1075.

[39] Ahn BJ, Le H, Shin MW, et al. The N-terminal ectodomain of Ninjurin1 liberated by MMP9 has chemotactic activity. Biochem Biophys Res Commun. 2012; 428(4): 438-444.

[40] Borges JP, Sætra RSR, Volchuk A, et al. Glycine inhibits NINJ1 membrane clustering to suppress plasma membrane rupture in cell death. eLife. 2022; 11:e78609.

[41] Shi J, Zhao Y, Wang K, et al. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature. 2015; 526(7575): 660-665.

[42] Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature. 2015; 517(7534): 311-320.

[43] Samson AL, Zhang Y, Geoghegan ND, et al. MLKL trafficking and accumulation at the plasma membrane control the kinetics and threshold for necroptosis. Nat Commun. 2020; 11(1): 3151.

[44] Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012; 149(5): 1060-1072.

[45] Hirata Y, Cai R, Volchuk A, et al. Lipid peroxidation increases membrane tension, Piezo1 gating, and cation permeability to execute ferroptosis. Curr Biol. 2023; 33(7): 1282-1294.e5.

[46] Noh H, Hashem Z, Boms E, Najafov A. SIGLEC12 mediates plasma membrane rupture during necroptotic cell death. Nature. 2026; 649(8096): 460-466.

[47] Augustin HG, Koh GY. A systems view of the vascular endothelium in health and disease. Cell. 2024; 187(18): 4833-4858.

[48] Lee HJ, Ahn BJ, Shin MW, Choi JH, Kim KW. Ninjurin1: a potential adhesion molecule and its role in inflammation and tissue remodeling. Mol Cells. 2010; 29(3): 223-227.

[49] Zheng XB, Wang X, Gao SQ, et al. NINJ1-mediated plasma membrane rupture of pyroptotic endothelial cells exacerbates blood‒brain barrier destruction caused by neutrophil extracellular traps in traumatic brain injury. Cell Death Discov. 2025; 11(1): 69.

[50] Han JH, Karki R, Malireddi RKS, et al. NINJ1 mediates inflammatory cell death, PANoptosis, and lethality during infection conditions and heat stress. Nat Commun. 2024; 15(1): 1739.

[51] Sun Z, Ma W, Ye F, Ren N, Shen K, Dong N. Ninjurin-1 drives atherosclerosis progression via NF-κB/CXCL-8 activation in endothelial cells. Front Immunol. 2025; 16:1676216.

[52] Hu W, Yang G, Ao L, et al. NINJ1 impairs the anti-inflammatory function of hUC-MSCs with synergistic IFN-γ and TNF-α stimulation. Chin J Traumatol Zhonghua Chuang Shang Za Zhi. 2025; 28(4): 276-287.

[53] Wang H, Kim SJ, Lei Y, et al. Neutrophil extracellular traps in homeostasis and disease. Signal Transduct Target Ther. 2024; 9(1): 235.

[54] Wang X, Qin J, Zhang X, et al. Functional blocking of Ninjurin1 as a strategy for protecting endothelial cells in diabetes mellitus. Clin Sci. 2018; 132(2): 213-229.

[55] Schachter J, Guijarro A, Angosto-Bazarra D, et al. Gasdermin D mediates a fast transient release of ATP after NLRP3 inflammasome activation before Ninjurin 1-induced lytic cell death. Cell Rep. 2025; 44(2):115233.

[56] Evavold CL, Ruan J, Tan Y, Xia S, Wu H, Kagan JC. The pore-forming protein Gasdermin D regulates interleukin-1 secretion from living macrophages. Immunity. 2018; 48(1): 35-44.e6.

[57] Choi H, Bae SJ, Choi G, et al. Ninjurin1 deficiency aggravates colitis development by promoting M1 macrophage polarization and inducing microbial imbalance. FASEB J. 2020; 34(6): 8702-8720.

[58] Ahn BJ, Le H, Shin MW, et al. Ninjurin1 enhances the basal motility and transendothelial migration of immune cells by inducing protrusive membrane dynamics. J Biol Chem. 2014; 289(32): 21926-21936.

[59] Embgenbroich M, van der Zande HJP, Hussaarts L, et al. Soluble mannose receptor induces proinflammatory macrophage activation and metaflammation. Proc Natl Acad Sci U S A 2021; 118(31):e2103304118.

[60] Hwang SJ, Ahn BJ, Shin MW, et al. miR-125a-5p attenuates macrophage-mediated vascular dysfunction by targeting Ninjurin1. Cell Death Differ. 2022; 29(6): 1199-1210.

[61] Cui J, Li H, Ye D, et al. Inhibiting NINJ1-dependent plasma membrane rupture protects against inflammasome-induced blood coagulation and inflammation. BioRxiv Prepr Serv Biol. 2024. 2023.08.30.555561.

[62] Grootaert MOJ, Bennett MR. Vascular smooth muscle cells in atherosclerosis: time for a re-assessment. Cardiovasc Res. 2021; 117(11): 2326-2339.

[63] Matsuo R, Kishibe M, Horiuchi K, et al. Ninjurin1 deletion in NG2-positive pericytes prevents microvessel maturation and delays wound healing. JID Innov Skin Sci Mol Popul Health. 2022; 2(6):100141.

[64] Jia M, Zhuo J, Zhao X, et al. Ninjurin2 regulates vascular smooth muscle cell phenotypic switching and vascular remodeling through interacting with PDGF receptor-β [Internet]. Pathology. 2025 [cited 2026 Feb 4]. http://biorxiv.org/lookup/doi/10.1101/2025.05.27.656052

[65] Saxena A, Russo I, Frangogiannis NG. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res J Lab Clin Med. 2016; 167(1): 152-166.

[66] Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet. 2018; 50(4): 524-537.

[67] Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro-Oncol. 2005; 7(4): 452-464.

[68] Matsuki M, Kabara M, Saito Y, et al. Ninjurin1 is a novel factor to regulate angiogenesis through the function of pericytes. Circ J. 2015; 79(6): 1363-1371.

[69] Horiuchi K, Kano K, Minoshima A, et al. Pericyte-specific deletion of ninjurin-1 induces fragile vasa vasorum formation and enhances intimal hyperplasia of injured vasculature. Am J Physiol Heart Circ Physiol. 2021; 320(6): H2438-H2447.

[70] Minoshima A, Kabara M, Matsuki M, et al. Pericyte-specific Ninjurin1 deletion attenuates vessel maturation and blood flow recovery in hind limb ischemia. Arterioscler Thromb Vasc Biol. 2018; 38(10): 2358-2370.

[71] Hill J, Rom S, Ramirez SH, Persidsky Y. Emerging roles of pericytes in the regulation of the neurovascular unit in health and disease. J Neuroimmune Pharmacol. 2014; 9(5): 591-605.

[72] Dong N, Wu X, Hong T, et al. Elevated serum Ninjurin-1 is associated with a high risk of large artery atherosclerotic acute ischemic stroke. Transl Stroke Res. 2023; 14(4): 465-471.

[73] Hur CJE, Steinberg BE. Targeting NINJ1-mediated cell rupture to treat inflammatory diseases. Mol Med. 2025; 31(1): 60.

[74] Chiong M, Wang ZV, Pedrozo Z, et al. Cardiomyocyte death: mechanisms and translational implications. Cell Death Dis. 2011; 2(12):e244.

[75] Shen J, Chen R, Duan S. NINJ1: bridging lytic cell death and inflammation therapy. Cell Death Dis. 2024; 15(11): 831.

[76] Zhang M, Liu Q, Meng H, et al. Ischemia‒reperfusion injury: molecular mechanisms and therapeutic targets. Signal Transduct Target Ther. 2024; 9(1): 12.

[77] Wang M, Li Y, Li S, Lv J. Endothelial dysfunction and diabetic cardiomyopathy. Front Endocrinol. 2022; 13:851941.

[78] Yanpiset P, Maneechote C, Sriwichaiin S, Siri-Angkul N, Chattipakorn SC, Chattipakorn N. Gasdermin D-mediated pyroptosis in myocardial ischemia and reperfusion injury: cumulative evidence for future cardioprotective strategies. Acta Pharm Sin B. 2023; 13(1): 29-53.

[79] Ketelut-Carneiro N, Fitzgerald KA. Apoptosis, pyroptosis, and necroptosis-oh my! The many ways a cell can die. J Mol Biol. 2022; 434(4):167378.

[80] Silvis MJM, Dengler SEKG, Odille CA, et al. Damage-associated molecular patterns in myocardial infarction and heart transplantation: the road to translational success. Front Immunol. 2020; 11:599511.

[81] Chen R, Zou J, Chen J, Zhong X, Kang R, Tang D. Pattern recognition receptors: function, regulation and therapeutic potential. Signal Transduct Target Ther. 2025; 10(1): 216.

[82] Tsuchiya K. Inflammasome-associated cell death: pyroptosis, apoptosis, and physiological implications. Microbiol Immunol. 2020; 64(4): 252-269.

[83] Xu X, Guan L, Tayier B, et al. Preliminary study of a Ninj1-loaded bimodal ultrasound/NIR fluorescence targeted molecular probe for diagnosing early-stage inflammation in coronary microvascular dysfunction. Adv Healthc Mater. 2026:e03403.

[84] Kloner RA, Brown DA, Csete M, et al. New and revisited approaches to preserving the reperfused myocardium. Nat Rev Cardiol. 2017; 14(11): 679-693.

[85] Zhu L, Xu Y. Multifaceted roles of ninjurin1 in immunity, cell death, and disease. Front Immunol. 2025; 16:1519519.

[86] Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac fibrosis: the fibroblast awakens. Circ Res. 2016; 118(6): 1021-1040.

[87] Amara M, Stoler O, Birati EY. The role of inflammation in the pathophysiology of heart failure. Cells. 2025; 14(14): 1117.

[88] Jin K, Ma Z, Wang X, et al. The role of cardiac macrophages in inflammation and fibrosis after myocardial ischemia‒reperfusion. Rev Cardiovasc Med. 2024; 25(11): 419.

[89] Nie F, Yu M, Liu M, Shang M, Zeng F, Liu W. NINJ2 gene polymorphisms and susceptibility to ischemic stroke: an updated meta-analysis. Curr Neurovasc Res. 2019; 16(3): 273-287.

[90] Xu T, Ding W, Ji X, Ao X, Liu Y, Yu W, et al. Oxidative stress in cell death and cardiovascular diseases. Oxid Med Cell Longev. 2019; 2019:9030563.

[91] Lee HK, Lee H, Luo L, Lee JK. Induction of nerve injury-induced protein 1 (Ninjurin 1) in myeloid cells in rat brain after transient focal cerebral ischemia. Exp Neurobiol. 2016; 25(2): 64-74.

[92] Xu Y, Zhang E, Wei L, et al. NINJ1: a new player in multiple sclerosis pathogenesis and potential therapeutic target. Int Immunopharmacol. 2024; 141:113021.

[93] Rai R, Naseem A, Vetharoy W, et al. An improved medium formulation for efficient ex vivo gene editing, expansion and engraftment of hematopoietic stem and progenitor cells. Mol Ther Methods Clin Dev. 2023; 29: 58-69.

[94] Zhang W, Liu H, Al-Shabrawey M, Caldwell RW, Caldwell RB. Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res. 2011; 2(2): 96-103.

[95] Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022; 23(6): 3346.

[96] Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018; 122(4): 624-638.

[97] Ramesh P, Yeo JL, Brady EM, McCann GP. Role of inflammation in diabetic cardiomyopathy. Ther Adv Endocrinol Metab. 2022; 13:20420188221083530.

[98] Zhou X, Xin G, Wan C, et al. The release of platelet DAMPs is regulated by NINJ1-mediated plasma membrane rupture. Indian J Hematol Blood Transfus. 2025; 41(3): 698-703.

[99] Chen SY, Lin CC, Wu J, et al. NINJ1 regulates ferroptosis via xCT antiporter interaction and CoA modulation [Internet]. Cancer Biology. 2024 [cited 2026 Feb 4]. http://biorxiv.org/lookup/doi/10.1101/2024.02.22.581432

[100] Sakuma M, Toyoda S, Inoue T, Node K. Inflammation in pulmonary artery hypertension. Vascul Pharmacol. 2019; 118–119:106562.

[101] Sakao S, Tatsumi K, Voelkel NF. Endothelial cells and pulmonary arterial hypertension: apoptosis, proliferation, interaction and transdifferentiation. Respir Res. 2009; 10(1): 95.

[102] Vonk Noordegraaf A, Chin KM, Haddad F, et al. Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J. 2019; 53(1):1801900.

[103] Sheng Y, Wu L, Chang Y, et al. Tomo-seq identifies NINJ1 as a potential target for anti-inflammatory strategy in thoracic aortic dissection. BMC Med. 2023; 21(1): 396.

[104] Wu Z, Xu Z, Pu H, et al. NINJ1 facilitates abdominal aortic aneurysm formation via blocking TLR4‒ANXA2 interaction and enhancing macrophage infiltration. Adv Sci. 2024; 11(31):e2306237.

[105] Dias C, Hornung V, Nylandsted J. A novel NINJ1-mediated regulatory step is essential for active membrane rupture and common to different cell death pathways. Fac Rev. 2022; 11: 41.

[106] denHartigh AB, Loomis WP, Anderson MJ, Frølund B, Fink SL. Muscimol inhibits plasma membrane rupture and ninjurin-1 oligomerization during pyroptosis. Commun Biol. 2023; 6(1): 1010.

[107] Zhang H, Zhang Y, Zhang C, et al. Recent advances of cell-penetrating peptides and their application as vectors for delivery of peptide and protein-based cargo molecules. Pharmaceutics. 2023; 15(8): 2093.

[108] Bezbaruah R, Chavda VP, Nongrang L, et al. Nanoparticle-based delivery systems for vaccines. Vaccines. 2022; 10(11): 1946.

[109] Vincent MP, Navidzadeh JO, Bobbala S, Scott EA. Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. Cancer Cell. 2022; 40(3): 255-276.

[110] Banerjee S, Cui H, Xie N, et al. miR-125a-5p regulates differential activation of macrophages and inflammation. J Biol Chem. 2013; 288(49): 35428-35436.

[111] Das D, Jothimani G, Banerjee A, Dey A, Duttaroy AK, Pathak S. A brief review on recent advances in diagnostic and therapeutic applications of extracellular vesicles in cardiovascular disease. Int J Biochem Cell Biol. 2024; 173:106616.

[112] Ho NPY, Takizawa H. Inflammation regulates haematopoietic stem cells and their niche. Int J Mol Sci. 2022; 23(3): 1125.

[113] Andrassy M, Volz HC, Igwe JC, et al. High-mobility group box-1 in ischemia‒reperfusion injury of the heart. Circulation. 2008; 117(25): 3216-3226.

[114] Averill MM, Kerkhoff C, Bornfeldt KE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol. 2012; 32(2): 223-229.

[115] Blankenberg S, Tiret L, Bickel C, et al. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002; 106(1): 24-30.

[116] Tarkin JM, Joshi FR, Rudd JHF. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 2014; 11(8): 443-457.

[117] Dhainaut M, Rose SA, Akturk G, et al. Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell. 2022; 185(7): 1223-1239.e20.

[118] McClements L, Kautzky-Willer A, Kararigas G, Ahmed SB, Stallone JN. The role of sex differences in cardiovascular, metabolic, and immune functions in health and disease: a review for “Sex differences in health awareness day.” Biol Sex Differ. 2025; 16(1): 33.

[119] Bai Y, Wu J, Jian W. Trained immunity in diabetes: emerging targets for cardiovascular complications. Front Endocrinol. 2025; 16:1533620.

[120] McCafferty CL, Klumpe S, Amaro RE, Kukulski W, Collinson L, Engel BD. Integrating cellular electron microscopy with multimodal data to explore biology across space and time. Cell. 2024; 187(3): 563-584.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.